ArticleCardiology research and practice2011
The Association of the Metabolic Syndrome with PAI-1 and t-PA Levels.
Article in Cardiology research and practice, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease.Journal of the American Heart Association · 2017Pooled it
- The role of PAI-1 and adiponectin on the inflammatory state and energy balance in obese adolescents with metabolic syndrome.Inflammation · 2012Trial
- The Serpin Superfamily in Adipose Tissue Remodeling: Molecular Drivers of Immune-Metabolic Crosstalk and Insulin Sensitivity.Biology · 2026Review
- Article
- Body composition and cardiometabolic risk reduction following therapy with a multi-ingredient nutraceutical formulation: a real-life clinical study.Drugs in context · 2026Article
- Obesity promotes radioresistance through SERPINE1-mediated aggressiveness and DNA repair of triple-negative breast cancer.Cell death & disease · 2023Article
- Genetic Polymorphisms in a Familial Hypercholesterolemia Population from North-Eastern Europe.Journal of personalized medicine · 2022Article
- Modulatory effect of filarial infection on the systemic hormone levels in subjects with metabolic syndrome (DM-LF5).Frontiers in endocrinology · 2022Article
- Circulating microparticle subpopulation in metabolic syndrome: relation to oxidative stress and coagulation markers.Diabetes, metabolic syndrome and obesity : targets and therapy · 2019Article
- Hypofibrinolytic State in Subjects with Type 2 Diabetes Mellitus Aggravated by the Metabolic Syndrome before Clinical Manifestations of Atherothrombotic Disease.BioMed research international · 2017Article
- A Case of Unexplained Cerebral Sinus Thrombosis in a 22-Year-Old Obese Caucasian Woman.Laboratory medicine · 2016Article
- Puzzling role of genetic risk factors in human longevity: "risk alleles" as pro-longevity variants.Biogerontology · 2016Review
- Altered Daytime Fluctuation Pattern of Plasminogen Activator Inhibitor 1 in Type 2 Diabetes Patients with Coronary Artery Disease: A Strong Association with Persistently Elevated Plasma Insulin, Increased Insulin Resistance, and Abdominal Obesity.International journal of endocrinology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
Background. We used a random sample (n = 2, 495) from the population-based Prevention of Renal and Vascular End-stage Disease (PREVEND) study population to examine the association of the metabolic syndrome (Met S) with plasminogen activator inhibitor type 1 (PAI-1) and tissue plasminogen activator (t-PA) antigen levels. Results. The overall prevalence of the Met S was 18%, was dependent on age and gender, and was positively associated with higher antigen levels of both PAI-1 and t-PA. These significant effects were maintained after adjustment for age, gender, BMI, elevated C-reactive protein, smoking status, urinary albumin excretion, and insulin levels. We found no significant interactions between the Met S and other covariates on PAI-1 and t-PA levels. Conclusions. Our study demonstrates that those with the Met S have significantly higher levels of PAI-1 and t-PA antigen, factors known to increase the risk of cardiovascular disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.